Sign up to save your podcasts
Or
Share How to Treat Cutaneous Melanoma in 2025 - Dr. Omid Hamid
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
How to Treat Cutaneous Melanoma in 2025 - Dr. Omid Hamid
In this episode of the Oncology Brothers podcast, we are joined by Dr. Omid Hamid, a melanoma specialist from Cedars-Sinai, to explore the current treatment landscape of cutaneous melanoma.
We covered a wide range of topics, including:
• The standard of care for early-stage melanoma, including wide local excision and sentinel lymph node evaluation.
• The role of adjuvant immunotherapy and BRAF/MEK inhibitors for high-risk patients.
• Insights into neoadjuvant treatment options for resectable disease, including recent trial data from NADINA and SWOG S1808.
• The importance of next-generation sequencing (NGS) and circulating tumor DNA (ctDNA) in treatment planning and monitoring.
• The evolving treatment paradigm for metastatic melanoma, including the use of dual checkpoint inhibitors and BRAF/MEK inhibitors.
Join us as we discuss the latest advancements in melanoma treatment and the critical role of patient education and shared decision-making in oncology care.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to subscribe for more episodes on treatment algorithms, new FDA approvals, and conference highlights!
#Melanoma #Immunotherapy #BRAF #ctDNA #Neoadjuvant #OncologyBrothers
View all episodes
By Oncology Brothers
4.8
3939 ratings
In this episode of the Oncology Brothers podcast, we are joined by Dr. Omid Hamid, a melanoma specialist from Cedars-Sinai, to explore the current treatment landscape of cutaneous melanoma.
We covered a wide range of topics, including:
• The standard of care for early-stage melanoma, including wide local excision and sentinel lymph node evaluation.
• The role of adjuvant immunotherapy and BRAF/MEK inhibitors for high-risk patients.
• Insights into neoadjuvant treatment options for resectable disease, including recent trial data from NADINA and SWOG S1808.
• The importance of next-generation sequencing (NGS) and circulating tumor DNA (ctDNA) in treatment planning and monitoring.
• The evolving treatment paradigm for metastatic melanoma, including the use of dual checkpoint inhibitors and BRAF/MEK inhibitors.
Join us as we discuss the latest advancements in melanoma treatment and the critical role of patient education and shared decision-making in oncology care.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to subscribe for more episodes on treatment algorithms, new FDA approvals, and conference highlights!
#Melanoma #Immunotherapy #BRAF #ctDNA #Neoadjuvant #OncologyBrothers
More shows like Oncology Brothers: Practice-Changing Cancer Discussions
View all
JAMA Editors' Summary
136 Listeners
NEJM This Week
323 Listeners
Journal of Clinical Oncology (JCO) Podcast
39 Listeners
Research To Practice | Oncology Videos
116 Listeners
JAMA Clinical Reviews
501 Listeners
ASCO Daily News
57 Listeners
JAMA Medical News
88 Listeners
Core IM | Internal Medicine Podcast
1,144 Listeners
The ONS Podcast
200 Listeners
OncoPharm
184 Listeners
ASCO Guidelines
44 Listeners
OncLive® On Air
21 Listeners
The Clinical Problem Solvers
514 Listeners
Oncology Today with Dr Neil Love
56 Listeners
Two Onc Docs
185 Listeners